Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab

Monoclonal antibodies targeting PD-1/PD-L1 signaling pathway have achieved unprecedented success in cancer treatment over the last few years. Atezolizumab is the first PD-L1 monoclonal antibody approved by US FDA for cancer therapy; however the molecular basis of atezolizumab in blocking PD-1/PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fei, Qi, Xiaoqiang, Wang, Xiaoxiao, Wei, Diyang, Wu, Jiawei, Feng, Lingling, Cai, Haiyan, Wang, Yugang, Zeng, Naiyan, Xu, Ting, Zhou, Aiwu, Zheng, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685743/
https://www.ncbi.nlm.nih.gov/pubmed/29163822
http://dx.doi.org/10.18632/oncotarget.21652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685743/
https://www.ncbi.nlm.nih.gov/pubmed/29163822
http://dx.doi.org/10.18632/oncotarget.21652

Ejemplares similares